CA2697520A1 - Utilisation des diaminophenothiazines reduites lyophilisees dans le traitement des troubles neurologiques a mediation par tau - Google Patents

Utilisation des diaminophenothiazines reduites lyophilisees dans le traitement des troubles neurologiques a mediation par tau Download PDF

Info

Publication number
CA2697520A1
CA2697520A1 CA2697520A CA2697520A CA2697520A1 CA 2697520 A1 CA2697520 A1 CA 2697520A1 CA 2697520 A CA2697520 A CA 2697520A CA 2697520 A CA2697520 A CA 2697520A CA 2697520 A1 CA2697520 A1 CA 2697520A1
Authority
CA
Canada
Prior art keywords
phenothiazine
gly
lys
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2697520A
Other languages
English (en)
Other versions
CA2697520C (fr
Inventor
Claude Michel Wischik
David Horsley
Janet Elizabeth Rickard
Charles Robert Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd.
Claude Michel Wischik
David Horsley
Janet Elizabeth Rickard
Charles Robert Harrington
The University Court Of The University Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd., Claude Michel Wischik, David Horsley, Janet Elizabeth Rickard, Charles Robert Harrington, The University Court Of The University Of Aberdeen filed Critical Wista Laboratories Ltd.
Publication of CA2697520A1 publication Critical patent/CA2697520A1/fr
Application granted granted Critical
Publication of CA2697520C publication Critical patent/CA2697520C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA2697520A 2001-01-15 2002-01-15 Utilisation des diaminophenothiazines reduites lyophilisees dans le traitement des troubles neurologiques a mediation par tau Expired - Lifetime CA2697520C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0101049.5A GB0101049D0 (en) 2001-01-15 2001-01-15 Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049.5 2001-01-15
CA2434067A CA2434067C (fr) 2001-01-15 2002-01-15 Materiaux et methodes permettant l'agregation des proteines dans une maladie neurogenerative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2434067A Division CA2434067C (fr) 2001-01-15 2002-01-15 Materiaux et methodes permettant l'agregation des proteines dans une maladie neurogenerative

Publications (2)

Publication Number Publication Date
CA2697520A1 true CA2697520A1 (fr) 2002-07-18
CA2697520C CA2697520C (fr) 2014-02-04

Family

ID=9906862

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2434067A Expired - Lifetime CA2434067C (fr) 2001-01-15 2002-01-15 Materiaux et methodes permettant l'agregation des proteines dans une maladie neurogenerative
CA2697520A Expired - Lifetime CA2697520C (fr) 2001-01-15 2002-01-15 Utilisation des diaminophenothiazines reduites lyophilisees dans le traitement des troubles neurologiques a mediation par tau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2434067A Expired - Lifetime CA2434067C (fr) 2001-01-15 2002-01-15 Materiaux et methodes permettant l'agregation des proteines dans une maladie neurogenerative

Country Status (14)

Country Link
US (2) US7335505B2 (fr)
EP (2) EP1352077B1 (fr)
JP (2) JP4422407B2 (fr)
CN (1) CN1496404B (fr)
AT (1) ATE483814T1 (fr)
AU (1) AU2002225147B2 (fr)
CA (2) CA2434067C (fr)
DE (1) DE60237874D1 (fr)
DK (2) DK1352077T3 (fr)
ES (2) ES2353202T3 (fr)
GB (1) GB0101049D0 (fr)
HK (2) HK1055605A1 (fr)
PT (2) PT2305823E (fr)
WO (1) WO2002055720A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US8288608B2 (en) * 2002-07-12 2012-10-16 Axon Neuroscience Se Transgenic animal expressing alzheimer's tau protein
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (fr) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Procedes de synthese chimique et de purification de composes diaminophenothiazinium renfermant du chlorure de methylthioninium (mtc)
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
AU2013200732B2 (en) * 2006-03-29 2015-04-09 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
CN101460222B (zh) * 2006-03-29 2013-12-04 维斯塔实验室有限公司 锍化合物及其用途
CN104119294B (zh) * 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
SI2167095T1 (sl) * 2007-06-19 2019-09-30 Wista Laboratories Ltd. Fenotiazinske spojine za zdravljenje blage kognitivne motnje
EP2954932B1 (fr) * 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Utilisation thérapeutique de diaminophénothiazines
US20110312059A1 (en) * 2008-08-20 2011-12-22 Oligomerix Inc. Tau protease compositions and methods
RU2518892C2 (ru) 2008-09-23 2014-06-10 Виста Лабораториз Лтд. Лиганды для агрегированных молекул тау-белка
CN102307878B (zh) * 2008-12-10 2014-10-15 维斯塔实验室有限公司 3,6-二取代的呫吨鎓盐
SI2430007T1 (sl) 2009-05-12 2014-05-30 Wista Laboratories Ltd. Postopki kemijske sinteze diaminofenotiazinijevih spojin, ki vključujejo uporabo persulfatnih oksidantov
JP6124591B2 (ja) * 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
PT2480541E (pt) 2009-09-24 2016-01-26 Wista Lab Ltd Hidratos de cloreto de metiltiónio cristalino (azul de metileno)
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
WO2011137447A1 (fr) 2010-04-30 2011-11-03 Prostetta Antiviral Inc. Composés antiviraux
EP2627357B1 (fr) 2010-10-15 2017-05-03 The Board of Regents of The University of Texas System Anticorps qui lient des oligomères amyloïdes
CA2818068C (fr) 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formules renfermant du chlorure de methylthioninium
CA2826286C (fr) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Traitement de tauopathies
SI2673266T1 (sl) 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG11201505195TA (en) * 2013-02-06 2015-08-28 Agency Science Tech & Res Methods For Reducing Aggregate Content In Protein Preparations
GB201317702D0 (en) 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
WO2015089375A1 (fr) * 2013-12-13 2015-06-18 The General Hospital Corporation Espèce tau soluble de poids moléculaire élevé (hmw) et ses applications
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン,インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
MY201804A (en) 2016-07-25 2024-03-19 Wista Laboratories Ltd Administration and dosage of diaminophenothiazines
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
CN113164563A (zh) * 2018-07-23 2021-07-23 因柯利尔疗法公司 神经性病症的治疗方法
EP3826650A4 (fr) 2018-07-23 2022-07-27 Enclear Therapies, Inc. Méthodes de traitement de troubles neurologiques
AU2019308873A1 (en) 2018-07-26 2021-02-04 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ, インク. 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
WO2023232764A1 (fr) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Traitement de troubles neurodégénératifs à l'aide de composés contenant du méthylthioninium (mt)
WO2024061971A1 (fr) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Nouvelles formulations et véhicules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE569430A (fr) * 1957-07-17
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
KR100231226B1 (ko) 1991-07-10 1999-11-15 스프레이그 로버트 월터 발수 처리용 및 발유 처리용 플루오로케미칼 조성물
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993003177A1 (fr) 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Nouvelles proteines kinases a neurofilament et tau
CA2125298A1 (fr) 1991-12-06 1993-06-10 Eva-Maria Mandelkow Outils pour le diagnostic et le traitement de la maladie d'alzheimer
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
CA2196529A1 (fr) 1994-08-08 1996-02-22 Peter Davies Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes
DE4430091A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5693638A (en) * 1996-02-23 1997-12-02 Myers; Daniel Method of treating a migraine headache
WO1999062548A1 (fr) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Procedes et compositions pour le diagnostic des pathologies tau
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
EP1248518A2 (fr) 2000-01-21 2002-10-16 PHARMACIA & UPJOHN COMPANY Modele murin transgenique de maladies neurodegeneratives humaines
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
WO2006032879A2 (fr) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Procedes de synthese chimique et de purification de composes diaminophenothiazinium renfermant du chlorure de methylthioninium (mtc)

Also Published As

Publication number Publication date
ES2353202T3 (es) 2011-02-28
GB0101049D0 (en) 2001-02-28
EP1352077B1 (fr) 2010-10-06
JP2004524831A (ja) 2004-08-19
JP4422407B2 (ja) 2010-02-24
ATE483814T1 (de) 2010-10-15
DE60237874D1 (de) 2010-11-18
EP2305823B1 (fr) 2013-03-27
US20090075984A1 (en) 2009-03-19
CA2697520C (fr) 2014-02-04
US7893054B2 (en) 2011-02-22
CA2434067C (fr) 2010-06-22
US20040110250A1 (en) 2004-06-10
EP2305823A1 (fr) 2011-04-06
ES2407204T3 (es) 2013-06-12
WO2002055720A9 (fr) 2002-12-27
DK1352077T3 (da) 2011-01-10
US7335505B2 (en) 2008-02-26
EP1352077A2 (fr) 2003-10-15
WO2002055720A3 (fr) 2002-11-21
JP5160990B2 (ja) 2013-03-13
AU2002225147B2 (en) 2006-12-07
JP2009035549A (ja) 2009-02-19
CN1496404A (zh) 2004-05-12
PT1352077E (pt) 2011-01-12
HK1149588A1 (en) 2011-10-07
DK2305823T3 (da) 2013-06-24
CN1496404B (zh) 2011-10-19
WO2002055720A2 (fr) 2002-07-18
CA2434067A1 (fr) 2002-07-18
HK1055605A1 (en) 2004-01-16
PT2305823E (pt) 2013-07-08

Similar Documents

Publication Publication Date Title
CA2697520A1 (fr) Utilisation des diaminophenothiazines reduites lyophilisees dans le traitement des troubles neurologiques a mediation par tau
WO2000061151A3 (fr) Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
NO20012984L (no) Succinoylamino benzodiazepiner som inhibitorer av AB proteinproduksjon
CA2382480A1 (fr) Derives de glucopyranosyloxypyrazole, compositions medicinales renfermant lesdits derives et produits intermediaires obtenus au cours de leur production
CA2379445A1 (fr) Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine .beta.
WO2004014881A3 (fr) Nouveaux composes
PL367814A1 (en) 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
HK1084941A1 (en) Compounds and their use
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
MA28038A1 (fr) Thienopyrazoles
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
HUE027064T2 (hu) Fokozott immunstimuláns aktivitású, hidrofób T-analógokat tartalmazó CPG oligonukleotid-analógok
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
CA2316919A1 (fr) Nouveaux macrolides
TW200502221A (en) Novel lactams and uses thereof
AP1408A (en) Phenyl yanthine derivatives.
GEP20032868B (en) Triazolo-Pyridazine Derivatives as Ligands for Gaba Receptors, Methods for Their Production, Pharmaceutical Compositions Containing the Same for Treatment and/or Prevention of disorders of Central Nervous System
US11466274B2 (en) Modified gapmer oligonucleotides and methods of use
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
WO2004112718A3 (fr) Composes, compositions et procedes permettant de traiter et de prevenir des infections a orthopoxvirus et des maladies associees
HUP0302333A2 (hu) Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
EP0911400A1 (fr) Composes antisens diriges contre cd14
NZ516290A (en) Substituted phenoxyacetic acids
CA2390029A1 (fr) Compositions pharmaceutiques

Legal Events

Date Code Title Description
EEER Examination request